Dose-adjusted lenalidomide combined with low-dose dexamethasone rescues older patients with bortezomib-resistant multiple myeloma

Satoshi Yamasaki, Kentaro Kohno, Masanori Kadowaki, Ken Takase, Seiichi Okamura

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)

抄録

Objective The aim of this study was to assess the safety and efficacy of lenalidomide (Len), with the dose adjusted according to the renal function, plus low-dose dexamethasone (Dex) in older patients with bortezomib (Bor)-resistant multiple myeloma (MM). Methods The study included 68 consecutive patients 70 years of age or older diagnosed with MM at our institute and ineligible for high-dose melphalan therapy plus autologous stem cell transplantation. Fifteen older patients with relapsed or refractory MM (RRMM) previously treated with Bor-containing regimens were treated with the combination of Len plus low-dose Dex. Results The median treatment duration was 12 months (range, 9 to 43 months), with all patients responding to Len plus low-dose Dex. All patients showed significant renal dysfunction between the beginning and end of treatment; however, the renal function improved in all cases. Conclusion Treatment with dose-adjusted Len combined with low-dose Dex is an effective and safe therapy for older RRMM patients exhibiting renal impairment after receiving Bor-based therapies.

本文言語英語
ページ(範囲)1711-1715
ページ数5
ジャーナルInternal Medicine
54
14
DOI
出版ステータス出版済み - 7 15 2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • 内科学

フィンガープリント

「Dose-adjusted lenalidomide combined with low-dose dexamethasone rescues older patients with bortezomib-resistant multiple myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル